Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment

INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairm...

Descripción completa

Detalles Bibliográficos
Autores principales: Giacomucci, Giulia, Mazzeo, Salvatore, Bagnoli, Silvia, Ingannato, Assunta, Leccese, Deborah, Berti, Valentina, Padiglioni, Sonia, Galdo, Giulia, Ferrari, Camilla, Sorbi, Sandro, Bessi, Valentina, Nacmias, Benedetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293849/
https://www.ncbi.nlm.nih.gov/pubmed/35288777
http://dx.doi.org/10.1007/s00415-022-11055-5
_version_ 1784749725518397440
author Giacomucci, Giulia
Mazzeo, Salvatore
Bagnoli, Silvia
Ingannato, Assunta
Leccese, Deborah
Berti, Valentina
Padiglioni, Sonia
Galdo, Giulia
Ferrari, Camilla
Sorbi, Sandro
Bessi, Valentina
Nacmias, Benedetta
author_facet Giacomucci, Giulia
Mazzeo, Salvatore
Bagnoli, Silvia
Ingannato, Assunta
Leccese, Deborah
Berti, Valentina
Padiglioni, Sonia
Galdo, Giulia
Ferrari, Camilla
Sorbi, Sandro
Bessi, Valentina
Nacmias, Benedetta
author_sort Giacomucci, Giulia
collection PubMed
description INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores. MATERIALS AND METHODS: We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis. Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement. Patients were classified as A + if they presented at least one positive amyloid biomarker or A− if not. RESULTS: NfL levels were significantly increased in AD and MCI compared to SCD patients. These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A−. Similarly, MCI A + had higher NfL levels than MCI A−, but comparable with AD. NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients. No correlations were found in AD subgroup. In SCD, NfL levels were negatively correlated with memory test scores. CONCLUSIONS: Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD.
format Online
Article
Text
id pubmed-9293849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92938492022-07-20 Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment Giacomucci, Giulia Mazzeo, Salvatore Bagnoli, Silvia Ingannato, Assunta Leccese, Deborah Berti, Valentina Padiglioni, Sonia Galdo, Giulia Ferrari, Camilla Sorbi, Sandro Bessi, Valentina Nacmias, Benedetta J Neurol Original Communication INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores. MATERIALS AND METHODS: We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis. Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement. Patients were classified as A + if they presented at least one positive amyloid biomarker or A− if not. RESULTS: NfL levels were significantly increased in AD and MCI compared to SCD patients. These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A−. Similarly, MCI A + had higher NfL levels than MCI A−, but comparable with AD. NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients. No correlations were found in AD subgroup. In SCD, NfL levels were negatively correlated with memory test scores. CONCLUSIONS: Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD. Springer Berlin Heidelberg 2022-03-14 2022 /pmc/articles/PMC9293849/ /pubmed/35288777 http://dx.doi.org/10.1007/s00415-022-11055-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Giacomucci, Giulia
Mazzeo, Salvatore
Bagnoli, Silvia
Ingannato, Assunta
Leccese, Deborah
Berti, Valentina
Padiglioni, Sonia
Galdo, Giulia
Ferrari, Camilla
Sorbi, Sandro
Bessi, Valentina
Nacmias, Benedetta
Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title_full Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title_fullStr Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title_full_unstemmed Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title_short Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
title_sort plasma neurofilament light chain as a biomarker of alzheimer’s disease in subjective cognitive decline and mild cognitive impairment
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293849/
https://www.ncbi.nlm.nih.gov/pubmed/35288777
http://dx.doi.org/10.1007/s00415-022-11055-5
work_keys_str_mv AT giacomuccigiulia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT mazzeosalvatore plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT bagnolisilvia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT ingannatoassunta plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT leccesedeborah plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT bertivalentina plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT padiglionisonia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT galdogiulia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT ferraricamilla plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT sorbisandro plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT bessivalentina plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment
AT nacmiasbenedetta plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment